Retatrutide, a novel dual agonist of the GLP-1 receptor and glucose-dependent insulinotropic polypeptide (GIP) target, is exhibiting promising outcomes in initial human trials . Recent inquiry indicates https://mediasocially.com/story6326989/retatrutide-emerging-studies-and-possible-medical-uses